Equity Profile

KNSA

Kiniksa Pharmaceuticals International, plc

Health CareBiotechnology$6.1B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kiniksa Pharmaceuticals International, plc is a biotechnology company focused on developing innovative therapies for patients with unmet medical needs. Operating in the health care sector, Kiniksa aims to address various conditions through its unique drug candidates, which could significantly impact patient outcomes and market dynamics.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, significantly beating expectations of $0.18, which led to a 23.48% increase in stock price the following day. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic ahead of the earnings report, especially after a strong performance last quarter. However, the lack of revenue guidance raises concerns about sustainability.

Bull Case

If Kiniksa continues to beat EPS expectations and provides positive revenue guidance, it could signal strong operational momentum and further stock price appreciation.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides disappointing revenue insights, it could lead to a significant decline in stock value, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's recent performance, the EPS figure will be crucial in determining market sentiment and stock movement.

Will Kiniksa provide any revenue guidance or updates on product pipeline developments?

Investors are keen to understand the company's growth trajectory and any potential risks associated with its product offerings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Kiniksa's ability to leverage recent product developments for revenue growth, especially given its strong EPS surprise last quarter.

Supporting Evidence

The company has consistently surprised on EPS, suggesting stronger operational efficiency than anticipated.

High implied volatility in options indicates that traders expect significant movement, which may not align with conservative analyst estimates.

Key Risk

If the EPS comes in above $0.30, it could challenge the current cautious consensus and lead to a reevaluation of growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Kiniksa's ability to maintain its recent earnings momentum while providing clarity on revenue growth.

Bull Confirmed If

An EPS of $0.30 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.18 would raise concerns about profitability and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience moderate movement as investors assess management's commentary.

Miss

A miss could result in a decline of approximately 6.58%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected launch timelines.
2Details on customer acquisition and retention strategies.
3Insights into market conditions affecting revenue growth.
4Management's outlook on competitive pressures in the biotechnology sector.
5Any commentary on potential partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Kiniksa continues to beat EPS expectations and provides positive revenue guidance, it could signal strong operational momentum and further stock price appreciation.

Bear Case

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's recent performance, the EPS figure will be crucial in determining market sentiment and stock movement.

Will Kiniksa provide any revenue guidance or updates on product pipeline developments?

Investors are keen to understand the company's growth trajectory and any potential risks associated with its product offerings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Kiniksa's ability to leverage recent product developments for revenue growth, especially given its strong EPS surprise last quarter.

Supporting Evidence

The company has consistently surprised on EPS, suggesting stronger operational efficiency than anticipated.

High implied volatility in options indicates that traders expect significant movement, which may not align with conservative analyst estimates.

Key Risk

If the EPS comes in above $0.30, it could challenge the current cautious consensus and lead to a reevaluation of growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Kiniksa's ability to maintain its recent earnings momentum while providing clarity on revenue growth.

Bull Confirmed If

An EPS of $0.30 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.18 would raise concerns about profitability and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests a potential stock increase of around 19.81%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience moderate movement as investors assess management's commentary.

Miss

A miss could result in a decline of approximately 6.58%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected launch timelines.
2Details on customer acquisition and retention strategies.
3Insights into market conditions affecting revenue growth.
4Management's outlook on competitive pressures in the biotechnology sector.
5Any commentary on potential partnerships or collaborations.